Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Kane Biotech reported robust financial performance in its fourth quarter and full year 2022 results, showing a 68% revenue increase to $691,654 for Q4, driven by growth in pet retail sales and licensing revenue. Total revenue for 2022 reached $2,668,352, a 66% increase from 2021. The company's gross profit surged 149% for the year to $1,413,229. Operating expenses decreased by 12%, leading to a 21% reduction in the annual loss to $3,824,000. Kane Biotech is focusing on advancing its clinical trials and expanding distribution agreements, including a notable partnership with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel. The company maintains a strong cash position of $1.1 million as of December 31, 2022.
Kane Biotech has signed a distribution agreement with ProgenaCare Global LLC to commercialize its coactiv+™ Antimicrobial Wound Gel in the U.S. market. ProgenaCare will exclusively distribute the product once Kane receives 510(k) clearance from the FDA, triggering a $500,000 USD upfront payment. This gel targets the $200 million USD U.S. wound care hydrogel market, addressing the significant issues of chronic wounds, which are often resistant to treatment due to bacterial biofilms. CEO Marc Edwards emphasized the partnership's potential to disrupt the fragmented market with innovative wound care solutions. Together, Kane Biotech and ProgenaCare aim to improve health outcomes for patients while making treatment more accessible.
Kane Biotech has entered into a licensing agreement with Skout’s Honor for its patented coactiv+™ technology, particularly in pet oral care applications. This ten-year agreement grants Skout’s Honor a non-exclusive license for use in North America, while STEM Animal Health, a joint venture of Kane Biotech, will continue to market its bluestem™ product line. As part of the agreement, STEM will receive a total of $500,000 USD in licensing fees plus ongoing royalties from Skout’s Honor's sales utilizing the coactiv+™ technology. This partnership is expected to enhance market reach and innovation in pet care products. However, Kevin Cole, president of STEM, will be leaving the company. Kane Biotech continues to focus on developing solutions targeting microbial biofilms.
Kane Biotech Inc. (OTCQB: KNBIF) will announce its Q4 and full-year 2022 financial results on April 20, 2023, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. Participants can register online for the call to receive dial-in details. Kane Biotech specializes in developing technologies to prevent and remove microbial biofilms, holding over 80 patents and trademarks. The company continues to focus on its research expertise to enhance its portfolio of biotechnologies and products.
Kane Biotech has signed a distribution agreement with Salud Pharma to launch its coactiv+™ Antimicrobial Hydrogel and DermaKB™ scalp care products in Colombia, Panama, and Costa Rica. The coactiv+™ product will be marketed through wound care centers and pharmacies after receiving FDA 510(k) approval. The DermaKB™ line addresses biofilm-related scalp conditions. This partnership aims to improve patient care in the region, responding to a significant need for advanced wound care solutions, given that over 80% of chronic wounds involve biofilm formation.
Kane Biotech reported third quarter 2022 financial results, achieving total revenue of $571,686, a 5% increase year-over-year. For the nine months ended September 30, 2022, revenue surged 65% to $1,976,698. License revenue soared 93% in Q3 to $69,411, while royalty revenue jumped 118% to $76,604. Gross profit rose 105% to $269,740 in Q3. Operating expenses decreased by 35% to $1,121,337. The company's loss narrowed 34% to $(1,039,091). Kane also submitted its first 510(k) application for the coactiv+™ Antimicrobial Wound Gel.
Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) will release its Q3 2022 financial results on November 24, 2022. The management team will host a conference call at 4:30 p.m. ET to discuss the results and recent business developments. Investors can pre-register for the call to receive dial-in details. Kane Biotech specializes in technologies for preventing and eliminating microbial biofilms and holds 81 patents. The company continues to engage in research and development aimed at commercialization.
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) has submitted a 510(k) premarket notification to the FDA for its new coactiv+™ Antimicrobial Hydrogel, designed for sensitive chronic wounds. Using patented coactiv+™ technology, this hydrogel aims to alleviate the challenges of treating chronic wounds, which often involve bacterial biofilms that resist treatment. The company anticipates favorable FDA reception, highlighting the significance of this technology in addressing the healthcare burden of chronic wounds.
Kane Biotech Inc. (OTCQB: KNBIF) announced its presentation at the Symposium on Advanced Wound Care (SAWC) Fall forum in Las Vegas, happening from October 13-16, 2022. This event focuses on advancing wound care practices through collaboration among various medical professionals. Dr. Gregory Schultz highlighted the significance of their DispersinB® Hydrogel and coactiv+® Antimicrobial Hydrogel in enhancing wound healing by combating biofilm formation. Kane Biotech emphasizes its commitment to improving patient outcomes through innovative wound care technologies.
Kane Biotech has secured an additional $425,000 USD in funding for its DispersinB® Hydrogel, contributing to a total of $2.7 million USD in non-dilutive funding received since 2020. This financial backing from the U.S. Department of Defense aims to advance clinical trials for treating biofilm-mediated antimicrobial resistance in chronic wounds. The DispersinB® Hydrogel shows promise in inhibiting biofilm formation, potentially accelerating wound closure and improving military readiness. The company emphasizes the clinical significance of its product amidst the high costs of chronic wound treatment.
FAQ
What is the current stock price of Kane Biotech (KNBIF)?
What is the market cap of Kane Biotech (KNBIF)?
